# Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes

> **NCT02380521** · PHASE4 · COMPLETED · sponsor: **University of Palermo** · enrollment: 60 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Exenatide once weekly (BYDUREON™)

## Key facts

- **NCT ID:** NCT02380521
- **Lead sponsor:** University of Palermo
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-07
- **Final completion:** 2016-11
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02380521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02380521, "Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT02380521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*